JUDITH A JAMES, MD, PHD
Osteopathic Medicine at 10 St, Oklahoma City, OK
License number
Oklahoma 19878
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
825 NE 10Th St, Oklahoma City, OK 73104
Phone
(405) 271-8478
(405) 271-4230 (Fax)
(405) 271-1515
(405) 271-4230 (Fax)
(405) 271-1515
Professional information
Dr. Judith A James, Oklahoma City OK - MD (Doctor of Medicine)
Specialties:
Rheumatology
Address:
OU Physicians Internal Medicine
825 NE 10Th St STE 4300, Oklahoma City 73104
(405) 271-3445 (Phone)
825 NE 10Th St STE 4300, Oklahoma City 73104
(405) 271-3445 (Phone)
Procedures:
Joint Drainage, Steroid Injections
Conditions:
Achilles Tendinitis, Arthritis, Behçet's Disease, Bursitis, Chronic Neck Pain, Degenerative Disc Disease, Fibromyalgia, Low Back Pain, Lupus Erythematosus, Osteoarthritis, Osteoarthritis of Hand or Wrist, Osteoarthritis of Knee, Osteopenia, Osteoporosis, Patellofemoral Pain Syndrome or Knee Pain, Raynaud's Disease, Rheumatoid Arthritis, Sarcoidosis, Sjögren's Syndrome, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis
Certifications:
Internal Medicine, 1998, Rheumatology, 2009
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
OU Physicians Internal Medicine
825 NE 10Th St STE 4300, Oklahoma City 73104
825 NE 10Th St STE 4300, Oklahoma City 73104
Education:
Medical School
University Of Oklahoma College Of Medicine
Graduated: 1994
University Of Ok College Of Med
University Of Oklahoma College Of Medicine
Graduated: 1994
University Of Ok College Of Med
Non-Human Animal Model For Systemic Lupus Erythematosis
US Patent:
6232522, May 15, 2001
Filed:
Nov 30, 1993
Appl. No.:
8/160604
Inventors:
John B. Harley - Oklahoma City OK
Judith A. James - Oklahoma City OK
R. Hal Scofield - Oklahoma City OK
Judith A. James - Oklahoma City OK
R. Hal Scofield - Oklahoma City OK
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK
International Classification:
C07K 500, A61K 3800, C12N 1585
US Classification:
800 9
Abstract:
A specific method has been developed to produce an autoimmune response and resulting clinical symptoms for a particular disease process. Peptides or other structures derived from an autoantigen and which are bound by auto antibody or T cell receptors are identified and used to induce an immune response. This immune response evolves into an autoimmune response directed against the other portions of the protein from which the peptide was derived. Subsequently, clinical manifestations may appear that are also found in the clinical illness. selected from the group including viruses, bacteria, fungi, parasites, rickettsia, plasmids, and insects which contains a structure or a peptide sequence that is similar to a structure or peptide sequence that has been identified by the method of claim 1 to the extent that it is bound by one of the group selected from antigen specific B cell surface receptors, and antigen specific T cell receptors.
Judith Ann James, Oklahoma City OK
Specialties:
Internal Medicine, Rheumatology, Medical Genetics
Work:
Oklahoma Medical Research
825 NE 13Th St, Oklahoma City, OK 73104 Oklahoma Universtiy Physicians
825 NE 10Th St, Oklahoma City, OK 73104 Oklahoma Medical Center Research Foundation
820 NE 15Th St, Oklahoma City, OK 73104
825 NE 13Th St, Oklahoma City, OK 73104 Oklahoma Universtiy Physicians
825 NE 10Th St, Oklahoma City, OK 73104 Oklahoma Medical Center Research Foundation
820 NE 15Th St, Oklahoma City, OK 73104
Education:
University of Oklahoma(1994)
Judith Ann James, Oklahoma City OK
Specialties:
Rheumatologist
Address:
825 Ne 13Th St, Oklahoma City, OK 73104
825 Ne 10Th St, Oklahoma City, OK 73104
825 Ne 10Th St, Oklahoma City, OK 73104
Education:
University of Oklahoma, College of Medicine - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Rheumatology (Internal Medicine)
Diagnostics And Therapy Of Epstein-Barr Virus In Autoimmune Disorders
US Patent:
7888458, Feb 15, 2011
Filed:
Jan 13, 1997
Appl. No.:
08/781296
Inventors:
John B. Harley - Oklahoma City OK, US
Judith A. James - Oklahoma City OK, US
Judith A. James - Oklahoma City OK, US
International Classification:
A61K 38/00, A61K 39/00, A61K 39/395, G01N 33/53
US Classification:
530300, 4241301, 4241841, 435 71
Abstract:
Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease. Cells infected with latent virus may also encourage autoimmunity.
Diagnostics And Therapy Of Epstein-Barr Virus In Autoimmune Disorders
US Patent:
7192715, Mar 20, 2007
Filed:
Oct 24, 2001
Appl. No.:
10/012756
Inventors:
John B. Harley - Oklahoma City OK, US
Judith A. James - Oklahoma City OK, US
Judith A. James - Oklahoma City OK, US
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK
International Classification:
G01N 33/53, A61K 38/04, A61K 38/16, A61K 38/245
US Classification:
435 71, 4242301, 4241851, 4241861, 530328, 530325
Abstract:
Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease. Cells infected with latent virus may also encourage autoimmunity.